Edap Tms (EDAP) Projected to Post Quarterly Earnings on Thursday

Edap Tms (NASDAQ:EDAP) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Edap Tms to post earnings of ($0.22) per share and revenue of $19.3110 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Edap Tms (NASDAQ:EDAP) last posted its earnings results on Wednesday, March 25th. The medical equipment provider reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.09). The company had revenue of $22.22 million for the quarter, compared to the consensus estimate of $21.28 million. Edap Tms had a negative net margin of 41.24% and a negative return on equity of 100.07%. On average, analysts expect Edap Tms to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Edap Tms Stock Performance

Shares of NASDAQ:EDAP traded up $0.16 during trading on Wednesday, hitting $3.61. 7,317 shares of the company traded hands, compared to its average volume of 55,970. The stock has a market capitalization of $135.30 million, a price-to-earnings ratio of -4.69 and a beta of -0.10. The business’s fifty day moving average is $3.74 and its 200-day moving average is $3.35. Edap Tms has a one year low of $1.21 and a one year high of $5.05. The company has a quick ratio of 1.19, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Analyst Upgrades and Downgrades

Several research firms have recently commented on EDAP. Wall Street Zen lowered Edap Tms from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. HC Wainwright reduced their price objective on Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Hedge Funds Weigh In On Edap Tms

An institutional investor recently bought a new position in Edap Tms stock. Kovack Advisors Inc. purchased a new stake in shares of Edap Tms S.A. (NASDAQ:EDAP) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 16,000 shares of the medical equipment provider’s stock, valued at approximately $53,000. 62.74% of the stock is owned by institutional investors.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.